Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 8/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.71 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.71 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 4/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28617390 | 1.00 | SLCO1B1 (0.71) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL22436313 | 1.00 | SLCO1B1 (0.71) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL22436315 | 1.00 | SLCO1B1 (0.71) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL29396987 | 1.00 | SLCO1B1 (0.71) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL20489316 | 0.93 | SLCO1B1 (0.69) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL21058073 | 0.92 | SLCO1B1 (0.70) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL22436305 | 0.92 | SLCO1B1 (0.70) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL21057960 | 0.92 | SLCO1B1 (0.70) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL21058078 | 0.92 | SLCO1B1 (0.70) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 | |
| SCHEMBL21057949 | 0.92 | SLCO1B1 (0.70) | SLCO1B1LPAR1ABCB11ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023001177-A1 | LPA1 SMALL MOLECULE ANTAGONIST | 上海拓界生物医药科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
| EP-3728224-B1 | CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3728224-B1 | CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-01-11 | — | — | EP | disclosed |
| US-RE49352-E1 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3728223-B1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220324829-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3666771-A1 | LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3472148-B1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-20 | — | — | US | disclosed |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | CHENG PETER TAI WAH (US) | 2018-11-22 | — | — | US | disclosed |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885LPAR1 2/4885ABCB11 2022/4885 |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885LPAR1 2/4885ABCB11 1766/4885 |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885LPAR1 2/4885ABCB11 2022/4885 |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885LPAR1 2/4885ABCB11 1766/4885 |
| US-20220324829-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885LPAR1 2/4885ABCB11 1766/4885 |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885LPAR1 2/4885ABCB11 2022/4885 |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885LPAR1 2/4885ABCB11 2022/4885 |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885LPAR1 2/4885ABCB11 1766/4885 |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885LPAR1 2/4885ABCB11 1766/4885 |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885LPAR1 2/4885ABCB11 1766/4885 |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885LPAR1 2/4885ABCB11 1766/4885 |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885LPAR1 2/4885ABCB11 2022/4885 |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885LPAR1 2/4885ABCB11 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.